Skip to main content

Multi-Market Submission Strategy

For manufacturers already registered or planning to register in the US, EU, Canada, or Australia, Mexico represents a strategically logical next step — particularly following the 2025 expansion of the Equivalency Route.

Leverage your existing approvals​

If you hold:

Existing approvalMexico pathway
FDA 510(k) / De Novo / PMAEquivalency Route — 30-working-day target
CE Mark (EU MDR)Equivalency Route — 30-working-day target
TGA registration (Australia)Equivalency Route — 30-working-day target
Health Canada licence (Class II+)Equivalency Route — 30-working-day target
No qualifying approvalStandard Route — 20–180 days by class

Prerequisite: The device must be identical to the approved foreign version.

Sequence: Mexico before or after other LATAM markets?​

Mexico is typically the first or second Latin American market for international manufacturers, usually entered alongside or just after:

  1. FDA (US) — if targeting North America, registering in the US first provides the most powerful Equivalency Route anchor for Mexico.
  2. ANVISA (Brazil) — the other large LATAM market; some manufacturers pursue Mexico and Brazil simultaneously.

A COFEPRIS registration then provides credibility and a documentation base for subsequent LATAM markets (Colombia, Argentina, Chile, Peru).

Documentation planning for COFEPRIS​

Even if you plan to use the Equivalency Route, prepare:

  • Spanish-language labelling early — this is required regardless of route and must be NOM-137 compliant.
  • Certificate of Free Sale from your reference authority — request this in advance as it may take time to obtain.
  • MRH appointment — identify and appoint your MRH before starting any submission.
  • Technovigilance procedures — your MRH must have these in place from day one.

Planning for renewal​

Build your registration lifecycle management process from the start:

  • 5-year renewal timeline — create a calendar reminder 18 months before expiry.
  • Technovigilance records — maintain complete records throughout the registration period for the Technovigilance Report at first renewal.
  • GMP surveillance — maintain current ISO 13485 / MDSAP certification for renewal.

Considerations for manufacturers not yet in FDA or EU markets​

If you do not have an FDA or CE Mark approval, the Standard Route is the pathway. Consider:

  • The Standard Route dossier for COFEPRIS closely parallels an FDA technical file or CE technical documentation — building one well serves multiple markets.
  • Consider ISO 13485 certification early — it satisfies NOM-241 for Mexico and GMP requirements for EU, Canada, and Australia simultaneously.